Wechselwirkungen von Balsalazid

Intervention: The concomitant use of Celecoxib with other NSAIDs or salicylates is not recommended. (Fachinformation zu Celecoxib, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended. (Fachinformation zu Diclofenac, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of diclofenac sodium/misoprostol with other NSAIDs or salicylates is not recommended. (Fachinformation zu Diclofenac und Misoprostol, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of fenoprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Fenoprofen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of flurbiprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Flurbiprofen, Arzneimittelwechselwirkungen)

The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Hydrocodon und Ibuprofen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Ibuprofen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of ibuprofen and famotidine tablet with other NSAIDs or salicylates is not recommended. (Fachinformation zu Ibuprofen und Famotidin, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of indomethacin with other NSAIDs or salicylates, especially diflunisal, is not recommended. (Fachinformation zu Indometacin, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of mefenamic acid with other NSAIDs or salicylates is not recommended. (Fachinformation zu Mefenaminsäure, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Meloxicam, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Naproxen, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with other NSAIDs or salicylates is not recommended. (Fachinformation zu Naproxen und Esomeprazol, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of oxaprozin with other NSAIDs or salicylates is not recommended. (Fachinformation zu Oxaprozin, Arzneimittelwechselwirkungen)

Intervention: The concomitant use of ibuprofen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Paracetamol und Ibuprofen, Arzneimittelwechselwirkungen)

Contraindications: ANTICHOLIUM ® should not be used in the presence of hypersensitivity to physostigmine salicylate, bronchial asthma, ulcers associated with tissue destruction (gangrene), coronary heart disease, constipation (mechanical obstipation), mechanical ischuria (urinary retention), hereditary form of muscle atrophy (myotonic dystrophy), closed traumatic… (Fachinformation zu Physostigmin, Gegenanzeigen)

Intervention: The concomitant use of piroxicam with other NSAIDs or salicylates is not recommended. (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

In patients on probenecid the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Fachinformation zu Probenecid, Warnhinweise)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (Fachinformation zu Probenecid und Colchicin, Warnhinweise)

Intervention: The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%. (Fachinformation zu Adapalen, Arzneimittelwechselwirkungen)

Azathioprine or 6-Mercaptopurine: Increased risk of blood disorders; monitor complete blood cell counts and platelet counts. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

• Rare instances of acid-base alterations have occurred with high-dose salicylate therapy. (Fachinformation zu Brinzolamid, Arzneimittelwechselwirkungen)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (Fachinformation zu Bromocriptin, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (Fachinformation zu Ciprofloxacin, Arzneimittelwechselwirkungen)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (Fachinformation zu Desogestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (Fachinformation zu Dexamethason, Arzneimittelwechselwirkungen)

Concomitant Use of Aspirin or Other Salicylates Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis [see Warnings and Precautions (5.4) ] , which can increase the risk of salicylate toxicity. (Fachinformation zu Diclofenamid, Warnhinweise und Vorsichtsmaßnahmen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid, Arzneimittelwechselwirkungen)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (Fachinformation zu Dorzolamid und Timolol, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid and temazepam. (Fachinformation zu Etonogestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

…sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin,… (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

• Salicylates : Risk of salicylate toxicity ( 7.1 ) (Fachinformation zu Furosemid, Arzneimittelwechselwirkungen)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly with salicylates. (Fachinformation zu Griseofulvin, Arzneimittelwechselwirkungen)

…agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically… (Fachinformation zu Humaninsulin (Normalinsulin), Arzneimittelwechselwirkungen)

• Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (Fachinformation zu Hyaluronidase, Arzneimittelwechselwirkungen)

The clearance of salicylates may be increased with concurrent use of corticosteroids; this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. (Fachinformation zu Hydrocortison, Arzneimittelwechselwirkungen)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors. (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

…May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Other Drugs Clinical effect Concomitant use of CHCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. (Fachinformation zu Levonorgestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

An initial increase in serum FT 4 is followed by return of FT 4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T 4 levels may decrease by as much as 30%. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. (Fachinformation zu Liothyronin, Arzneimittelwechselwirkungen)

Azathioprine or 6-Mercaptopurine: Increased risk of blood disorders; monitor complete blood cell counts and platelet counts. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Mesalamine-Induced Acute Intolerance Syndrome: Symptoms may be difficult to distinguish from an exacerbation of ulcerative colitis; monitor for worsening symptoms; discontinue treatment if acute intolerance syndrome is suspected. (Fachinformation zu Balsalazid, Warnhinweise und Vorsichtsmaßnahmen)

Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate, including XATMEP. (Fachinformation zu Methotrexat, Arzneimittelwechselwirkungen)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (Fachinformation zu Methylprednisolon, Arzneimittelwechselwirkungen)

Salicylates And Other Non-Steroidal Anti-Inflammatory Drugs May decrease the antihypertensive effects of metolazone tablets, USP. (Fachinformation zu Metolazon, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

…with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan,… (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Fachinformation zu Natriumphenylacetat und Natriumbenzoat, Warnhinweise und Vorsichtsmaßnahmen)

In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently. (Fachinformation zu Nizatidin, Arzneimittelwechselwirkungen)

CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam. (Fachinformation zu Norelgestromin und Ethinylestradiol, Arzneimittelwechselwirkungen)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (Fachinformation zu Norgestimat und Ethinylestradiol, Arzneimittelwechselwirkungen)

COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. (Fachinformation zu Norgestrel und Ethinylestradiol, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

…sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antacids Antacids may affect absorption of phenytoin. (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

NSAIDS, including aspirin and salicylates: Concomitant use of aspirin or other non-steroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. (Fachinformation zu Prednisolon, Arzneimittelwechselwirkungen)

NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (Fachinformation zu Prednison, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Conversely, agents such as indomethacin, probenecid and salicylates may displace sulfonamides from plasma albumin and increase the concentrations of free drug in plasma. (Fachinformation zu Sulfadiazin, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

Nonsteroidal Anti-Inflammatory Drugs Because torsemide and salicylates compete for secretion by renal tubules, patients receiving high doses of salicylates may experience salicylate toxicity when torsemide is concomitantly administered. (Fachinformation zu Torasemid, Arzneimittelwechselwirkungen)

The clearance of salicylates may be increased with concurrent use of corticosteroids. (Fachinformation zu Triamcinolon, Arzneimittelwechselwirkungen)

Coadministration of aspirin 150 mg/day with multiple daily doses of TRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Vortioxetin, Arzneimittelwechselwirkungen)

These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. (Fachinformation zu Enoxaparin, Arzneimittelwechselwirkungen)

In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam. (Fachinformation zu Entacapon, Vorsichtsmaßnahmen)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. (Fachinformation zu Balsalazid, Warnhinweise und Vorsichtsmaßnahmen)